Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEG35156 + Gemcitabine in Advanced Pancreatic Cancer
NCT00557596Phase 2Terminated
- Sponsor
- Aegera Therapeutics
- Start
- Sep 2007
- Primary completion
- Nov 2009
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of AEG35156 in pancreatic adenocarcinoma (PDAC), sponsored by Aegera Therapeutics. Started Sep 2007; status: terminated.
02
Drugs
AEG35156
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00557596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557596.